DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Alzheimer disease — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlzheimer disease maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alzheimer disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NCK adaptor protein 2 (NCK2) — NCK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ipadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2CIA · 1.45 Å · ligand ISOPROPYL ALCOHOL (IPA). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2006 · 0 citations
Alzheimer's Disease: A Physician's Guide to Practical Management
AbstractAlzheimer's Disease: A Physician's Guide to Practical Management
edited by R.W. Richter and B.Z. Richter, 479 pp., Humana Press, 2004, $99.50
The editors of this book have assembled an impressive cast of 74 authors, most of whom are well recognized authorities in the field, while some are very promising young scientists. It has 51 chapters arranged in 11 sections. It covers the traditional aspects of scientific background, epidemiology, clinical assessment, treatment options, late stage therapy, neuropsychiatric management, and family care issues. In addition, it covers some timely topics such as outcome measurement, the transitional stage before clinical Alzheimer disease (AD), prevention …
The Journal of Clinical Psychiatry · 2021 · 0 citations
Advances in Diagnosis of Alzheimer Disease and Emerging Treatment Targets
AbstractUntil recently, the diagnosis of Alzheimer disease (AD) could not be truly made until an autopsy was done. Patients' diagnosis relied on clinicians' skills to recognize signs and symptoms of AD, and the diagnosis was often incorrect. The rate of misdiagnosis was higher in earlier disease stages when symptoms are milder. Researchers have made great strides over the past 2 decades in identifying diagnostic biomarkers and treatment targets. Can AD now be diagnosed before patients show symptoms? What do potential treatments look like? This CME presentation highlights exciting developments.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
